Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put GlaxoSmithKline Inc. GSK stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, GlaxoSmithKline has a trailing twelve months PE ratio of 14.3, as you can see in the chart below:
This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 20.3. If we focus on the long-term PE trend, GlaxoSmithKline’s current PE level puts it above its midpoint over the past five years, with the number having risen rapidly over the past few months.
Further, the stock’s PE also compares favorably with the industry’s trailing twelve months PE ratio, which stands at 16.5 At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.
We should also point out that GlaxoSmithKline has a forward PE ratio (price relative to this year’s earnings) of just 14.1, so it is fair to say that a slightly more value-oriented path may be ahead for GlaxoSmithKline stock in the near term too.
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, GlaxoSmithKline has a P/S ratio of about 2.3. This is a bit lower than the S&P 500 average, which comes in at 3.2x right now. Also, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.
If anything, GSK is in the lower end of its range in the time period from a P/S metric, suggesting some level of undervalued trading—at least compared to historical norms.
Broad Value Outlook
In aggregate, GlaxoSmithKline currently has a Value Score of B, putting it into the top 40% of all stocks we cover from this look. This makes GlaxoSmithKline a solid choice for value investors, and some of its other key metrics make this pretty clear too.
For example, the PEG ratio for GlaxoSmithKline is just 2.1, a level that is lower than the industry average of 2.4. The PEG ratio is a modified PE ratio that takes into account the stock’s earnings growth rate. Clearly, GSK is a solid choice on the value front from multiple angles.
What About the Stock Overall?
Though GlaxoSmithKline might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of B and a Momentum Score of A. This gives GSK a Zacks VGM score — or its overarching fundamental grade — of A. (You can read more about the Zacks Style Scores here >>)
Meanwhile, the company’s recent earnings estimates have been pretty encouraging. The current quarter has seen one estimate go higher in the past sixty days compared to one lower, while the full year estimate has seen one up and two down in the same time period.
This has had a significant impact on the consensus estimate as the current quarter consensus estimate has risen by 7.6% in the past two months, and the full year estimate has inched up by 0.7%. You can see the consensus estimate trend and recent price action for the stock in the chart below:
GlaxoSmithKline PLC Price and Consensus
GlaxoSmithKline PLC Price and Consensus | GlaxoSmithKline PLC Quote
Despite this favorable trend, the stock has just a Zacks Rank #3 (Hold) and that why we are looking for better performance from the company in the near term.
GlaxoSmithKline is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Moreover, a strong industry rank (Top 21% out of more than 250 industries) further strengthens its growth potential. In fact, over the past six months, the industry has clearly outperformed the broader market, as you can see below:
So, despite a Zacks Rank #3, we believe that bullish analyst sentiment and favorable industry factors make this value stock a compelling pick
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. GlaxoSmithKline sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GlaxoSmithKline PLC (GSK) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research